Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
14.10
+1.24 (9.64%)
At close: May 9, 2025, 4:00 PM
14.06
-0.04 (-0.28%)
After-hours: May 9, 2025, 7:40 PM EDT
Spyre Therapeutics Stock Forecast
Stock Price Forecast
According to 6 professional analysts, the 12-month price target for Spyre Therapeutics stock ranges from a low of $40 to a high of $65. The average price target of $50 forecasts a 254.61% increase in the stock price over the next year.
Price Target: $50.00 (+254.61%)
Analyst Consensus: Buy
* Price targets were last updated on Apr 8, 2025.
Analyst Ratings
The average analyst rating for Spyre Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
---|---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 2 | 2 |
Buy | 4 | 4 | 4 | 4 | 5 | 5 |
Hold | 1 | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 8 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Leerink Partners | Leerink Partners | Buy Initiates $45 | Buy | Initiates | $45 | +219.15% | Apr 8, 2025 |
Jones Trading | Jones Trading | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Dec 11, 2024 |
Baird | Baird | Buy Maintains $50 → $65 | Buy | Maintains | $50 → $65 | +360.99% | Nov 13, 2024 |
Guggenheim | Guggenheim | Strong Buy Maintains $50 → $65 | Strong Buy | Maintains | $50 → $65 | +360.99% | Oct 25, 2024 |
Wedbush | Wedbush | Buy Initiates $45 | Buy | Initiates | $45 | +219.15% | Sep 4, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-3.51
from -3.18
EPS Next Year
-3.56
from -3.51
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | n/a | n/a | n/a | ||
Avg | n/a | n/a | n/a | ||
Low | n/a | n/a | n/a |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -1.83 | -2.08 | -1.71 | ||
Avg | -3.51 | -3.56 | -3.86 | ||
Low | -4.31 | -5.06 | -5.81 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.